NIR Activated Multimodal Therapeutics Based on Metal–Phenolic Networks‐Functionalized Nanoplatform for Combating against Multidrug Resistance and Metastasis

Multidrug resistance (MDR) and metastasis in cancer have become increasingly serious problems since antitumor efficiency is greatly restricted by a single therapeutic modality and the insensitive tumor microenvironment (TME). Herein, metal–phenolic network‐functionalized nanoparticles (t‐P@TFP NPs) are designed to realize multiple therapeutic modalities and reshape the TME from insensitive to sensitive under multimodal imaging monitoring. After a single irradiation, a near‐infrared laser‐activated multistage reaction occurs. t‐P@TFP NPs trigger the phase transition of perfluoropentane (PFP) to release tannic acid (TA)/ferric ion (Fe3+)‐coated paclitaxel (PTX) and cause hyperthermia in the tumor region to efficiently kill cancer cells. Additionally, PTX is released after the disassembly of the TA‐Fe3+ film by the abundant adenosine triphosphate (ATP) in the malignant tumor, which concurrently inhibits ATP‐dependent drug efflux to improve sensitivity to chemotherapeutic agents. Furthermore, hyperthermia‐induced immunogenic cell death (ICD) transforms “cold” tumors into “hot” tumors with the assistance of PD‐1/PD‐L1 blockade to evoke antitumor immunogenicity. This work carefully reveals the mechanisms underlying the abilities of these multifunctional NPs, providing new insights into combating the proliferation and metastasis of multidrug‐resistant tumors. A novel nanoplatform that can realize multiple therapeutic modalities and reshape the tumor microenvironment from insensitive to sensitive under multimodal‐imaging monitoring is constructed. After a single near‐infrared laser irradiation, t‐P@TFP NPs release metal–phenolic networks‐functionalized paclitaxel (PTX) for sensitized chemo‐photothermal therapy. Additionally, hyperthermia‐triggered immunogenic cell death (ICD) enhances the antitumor immune response to suppress metastasis with the assistance of PD‐1/PD‐L1 blockade.